Powered by

Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001(TM)

Nov 20, 2018 - Business Wire

Bioasis Technologies Inc.  (TSX.V:BTI; OTCQB:BIOAF) (the "Company"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 (TM) platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced data using the Company's lead investigational candidate xB3-001 in an advanced positron emission ...